Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myelomonocytic, Chronic 1

Interventions

Peripheral Blood Stem Cell Transplantation 5fludarabine phosphate 4Cyclosporine 3Cyclophosphamide 3Whole-Body Irradiation 2Tacrolimus 2Pentetic Acid 2Mycophenolic Acid 2Methotrexate 2Filgrastim 2Cytarabine 2Cyclosporins 2Busulfan 2Azacitidine 2venetoclax 1tamibarotene 1olutasidenib 1merphos 1ethanolamine oleate 1decitabine and cedazuridine drug combination 1bisantrene 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Therapeutics 1Sulfamethoxazole 1Sodium Chloride 1Sitagliptin Phosphate 1Saline Solution, Hypertonic 1Saline Solution 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Leukemia, Myelomonocytic, Chronic × tamibarotene × Clear all
NCT06085638 2024-03-07

Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Other hematologic neoplasm

Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡